Conclusions
Increased understanding of the role of systemic and cardiac metabolism impairments in heart failure not only generates new pathophysiological concepts, but also stimulates the search for new therapies for patients with heart failure. Trimetazidine effectively regulates cardiac energy metabolism by reducing fatty acid oxidation and increasing glucose oxidation and its potential should be considered for add-on therapy with conventional treatment of heart failure.